Hypothesis

Fibrillar Aβ deposition initiates a localized increase in extracellular matrix (ECM) viscoelasticity through exosome‑mediated oligomer cross‑linking of heparan sulfate proteoglycans (HSPGs). This altered biomechanical state raises the effective percolation threshold for tau polymer growth, thereby gating the spread of pathological tau along the structural‑functional connectome. In regions where Aβ‑induced ECM stiffening remains below the threshold (e.g., basal ganglia), tau propagation is attenuated despite strong connectivity, explaining the off‑target mismatch observed in pure network models.

Mechanistic Basis

• Aβ oligomers secreted in exosomes bind HSPGs, nucleating reversible cross‑links that increase ECM storage modulus (G′) as described by polymer gel theory (4).
• Elevated G′ augments neuronal membrane tension, activating mechanosensitive pathways (e.g., YAP/TAZ) that phosphorylate tau at sites favoring detachment from microtubules and reducing its propensity to seed (6).
• The ECM acts as a tunable sieve: tau fibrils can only propagate when local Aβ‑driven stiffening falls below a critical gel point, a concept borrowed from nucleation‑polymerization models applied to extracellular gels (1).
• This mechanism reconciles the near‑simultaneous cortical Aβ deposition (5) with the slower, connectivity‑guided tau spread (2).

Testable Predictions

1. Biophysical prediction: In vitro ECM enriched with neuronal exosomes containing Aβ oligomers will show a statistically significant increase in G′ (measured by rheology) correlating with reduced tau fibril elongation rates in seeded assays.
2. Cellular prediction: Knockdown of exosomal HSPG‑binding proteins (e.g., syndecan‑1) in primary neurons will attenuate Aβ‑induced ECM stiffening and rescue tau propagation in microfluidic axon‑tract assays.
3. In vivo prediction: AD model mice treated with an exosome release inhibitor (GW4869) will exhibit lower cortical ECM modulus (via atomic force microscopy) and attenuated tau‑PET signal in basal ganglia despite unchanged cortical Aβ load.
4. Clinical prediction: CSF exosomal Aβ oligomer concentration will inversely correlate with basal ganglia tau‑PET uptake across the ADNI longitudinal cohort, after controlling for global amyloid burden.

Experimental Design

• In vitro: Prepare hippocampal neuron‑derived exosomes, isolate Aβ‑rich fractions, mix with purified HSPGs, and perform oscillatory shear rheology to map G′ versus oligomer concentration. Parallel Thioflavin‑T tau seeding assays quantify lag phase and growth rate.
• In vivo: Use APP/PS1 mice crossed with tau‑P301S line; administer GW4869 or vehicle for 3 months. Ex vivo brain slices undergo AFM mapping; tau pathology assessed by AT8 immunohistochemistry and PET‑compatible autoradiography.
• Human data: Analyze ADNI baseline CSF exosomes (NanoAβ‑ELISA), cortical SUVR (amyloid‑PET), and basal ganglia tau‑SUVR (tau‑PET). Apply mixed‑effects modeling to test the inverse interaction term.

Potential Implications

If validated, this hypothesis positions the ECM as a dynamic, material‑state checkpoint that couples nanoscale Aβ oligomer physics to macroscale network pathology. It suggests therapeutic strategies targeting exosomal ECM remodeling—rather than Aβ clearance alone—could decouple tau spread from amyloid burden, particularly in resilient subcortical circuits.